Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 63-69 , October 2004

Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population

  • Yoshiharu Tokuyama

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-43-232-3691; fax: +81-43-232-9100.
    • ,
  • Kana Matsui

      Affiliations

    • Division of Clinical Department, Research and Development Center, BML Inc., Kawagoe, Japan
    • ,
  • Toru Egashira

      Affiliations

    • Division of Clinical Department, Research and Development Center, BML Inc., Kawagoe, Japan
    • ,
  • Osamu Nozaki

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
    • ,
  • Toshiharu Ishizuka

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
    • ,
  • Azuma Kanatsuka

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan

Received 25 November 2003 ,Revised 27 January 2004 ,Accepted 10 February 2004.

References 

  1. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diab. Metab. Rev. 1992;8:149–177
  2. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 1995;16:390–410
  3. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic β cell function. Eur. J. Endocrinol. 2000;143:717–725
  4. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51:1443–1452
  5. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137:2968–2978
  6. Thorens B. Expression cloning of the pancreatic β-cell receptor for the gluco-incretin hormone glucagon peptide-1. Proc. Natl. Acad. Sci. U.S.A. 1992;89:8641–8645
  7. Scrocchi LA, Brown TJ, MacLusky N, et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 1996;2:1254–1258
  8. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes. 1998;47:632–639
  9. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992;326:1316–1322
  10. Nauck M. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diab. Med. 1996;13:S39–S43
  11. Drucker DJ. Development of glucagons-like peptide 1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr. Pharm. Design. 2001;7:1399–1412
  12. Bloomgarden ZT. Treatment issues in type 2 diabetes. Diab. Care. 2002;25:614–619
  13. Kanatsuka A, Tokuyama Y, Nozaki O, Matsui K, Egashira T. β-Cell dysfunction in late-onset diabetic subjects carrying homozygous mutation in transcription factors NeuroD1 and Pax4. Metabolism. 2002;51:1161–1165
  14. World Health Organization, Diabetes Mellitus: Report of WHO Study Group, WHO Technical Report Series, No. 727, Geneva, Switzerland, 1985.
  15. Tokuyama Y, Sakurai K, Yagui K, Hashimoto N, Saito Y, Kanatsuka A. Pathophysiologic phenotypes of Japanese subjects with varying degrees of glucose tolerance: using the combination of C-peptide secretion rate and minimal model analysis. Metabolism. 2001;50:812–818
  16. Eaton RP, Allen RC, Schade DS, Erickso KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J. Clin. Endocr. Metab. 1980;51:520–528
  17. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am. J. Physiol. 1979;236:E667–E677
  18. Tanizawa Y, Riggs AC, Elbein SC, Whelan A, Donis-Keller H, Permutt MA. Human glucagon-like peptide 1 receptor gene in NIDDM: identification and use of simple sequence repeat polymorphisms in genetic analysis. Diabetes. 1994;43:752–757
  19. Zhang Y, Cook JTE, Hattersley AT, et al.  Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young. Diabetologia. 1994;37:721–724
  20. Xu G, Stoffer DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276
  21. D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 1994;93:2263–2266
  22. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830
  23. Wilmen A, Goke B, Goke R. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP-1) receptor has intrinsic binding activity. FEBS Lett. 1996;398:43–47
  24. Heller RS, Kieffer TJ, Habener JF. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling. Biochem. Biophys. Res. Commun. 1996;223:624–632
  25. Bavec A, Hallbrink M, Langel U, Zorko M. Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regul. Pept. 2003;28:137–144
  26. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion. Effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380–386
  27. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(1):95–202
  28. Ahren B, Sandqvist M, Simonsson et E, et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diab. Care. 2002;25:869–875

PII: S0168-8227(04)00049-X

doi: 10.1016/j.diabres.2004.02.004

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 63-69 , October 2004

Article Tools

* Image Usage & Resolution